Monitoring inflammatory activity in inflammatory bowel disease: not too far, not too close.

Abstract

Treat-to-target in Inflammatory Bowel Disease aims to achieve symptomatic remission, normalization of biomarkers such as fecal calprotectin, and endoscopic remission within defined timeframes. Early recognition of inflammatory activity and timely therapeutic intervention are essential for improving the quality of life of patients with Inflammatory Bowel Disease.